Saltar al contenido
Ebusca Home
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
Avanzado
  • Use of multiple laboratory tes...
  • Citar
  • Imprimir
  • Exportar Registro
    • Exportar a RefWorks
    • Exportar a EndNoteWeb
    • Exportar a EndNote
  • Enlace Permanente
Cargando…

Use of multiple laboratory tests including anti-factor Xa to optimally manage anticoagulation during ECMO

Detalles Bibliográficos
Autores principales: Honore, Patrick M., Barreto Gutierrez, Leonel, Kugener, Luc, Redant, Sebastien, Attou, Rachid, Gallerani, Andrea, De Bels, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358299/
https://www.ncbi.nlm.nih.gov/pubmed/32660540
http://dx.doi.org/10.1186/s13054-020-03145-5
  • Existencias
  • Descripción
  • Ejemplares similares
  • Vista Equipo

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358299/
https://www.ncbi.nlm.nih.gov/pubmed/32660540
http://dx.doi.org/10.1186/s13054-020-03145-5

Ejemplares similares

  • Risk of harlequin syndrome during bi-femoral peripheral VA-ECMO: should we pay more attention to the watershed or try to change the venous cannulation site?
    por: Honore, Patrick M., et al.
    Publicado: (2020)
  • TPE seems to be a treatment that may improve outcomes by effectively removing fibrin degradation products and restoring coagulation status: fact or fiction?
    por: Honore, Patrick M., et al.
    Publicado: (2020)
  • High doses of tigecycline are associated with satisfactory plasmatic and pulmonary concentrations for the treatment of severe infections due to fully susceptible bacteria: do we need even higher doses in patients under CRRT?
    por: Honore, Patrick M., et al.
    Publicado: (2020)
  • Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider
    por: Honore, Patrick M., et al.
    Publicado: (2020)
  • Mortality in non-elderly septic patients was increased with hypothermia and decreased with fever while mortality in elderly patients was not associated with body temperature: beware of some confounders!
    por: Honore, Patrick M., et al.
    Publicado: (2020)

Opciones de búsqueda

  • Historial de Búsqueda
  • Búsqueda Avanzada

Buscar Más

  • Revisar el Catálogo
  • Lista Alfabética
  • Explorar canales
  • Reservas de Curso
  • Nuevos ejemplares

¿Necesita Ayuda?

  • Consejos de búsqueda
Cannot write session to /tmp/vufind_sessions/sess_anm80jdhrv2bt2r08m0s9r1sav